About this episode
The episode discusses the genetics of cannabis lifetime use and its implications for cannabis use disorder.
Cannabis, which is increasingly legally available, both for therapeutic and recreational use, is now one of the most commonly used drugs worldwide. Of people who have ever used cannabis, studies vary, but they estimate that about 10-25 percent of people who use cannabis go on to develop cannabis use disorder. Uri Bright is a postdoctoral associate at the Yale School of Medicine and is one of the authors of a recent study in the journal Neuropsychopharmacology on the genetics of cannabis lifetime use — which is anyone who has ever used cannabis even once. That’s a distinct population from people who have cannabis use disorder, as his colleagues had looked into in the previous study. Hosted on Acast. See acast.com/privacy for more information.
People in this episode
Guest: Uri Bright
Topics covered
- cannabis
- genetics
- cannabis use disorder
- therapeutic use
- recreational use
Keywords
- cannabis
- genetics
- use disorder
- therapeutic use
- recreational use
- lifetime use
Mentioned in this episode
Organizations: Yale School of Medicine, Neuropsychopharmacology, Springer Nature
More episodes of NPP BrainPod
- Incentive salience, not psychomotor sensitization or tolerance, drives escalation of cocaine self-administration in heterogeneous stock rats · May 15, 2026 · 10 min
- Oxytocin neurons in the anterior and posterior paraventricular nucleus have distinct behavioral functions and electrophysiological profiles · February 23, 2026 · 10 min
- Older and wiser? The neural correlates of worry induction and reappraisal in older adults · October 27, 2025 · 10 min
- Grey matter morphometry in young adult e-cigarette users, tobacco cigarette users & non-using controls · July 29, 2025 · 9 min
- Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records · June 4, 2025 · 10 min
- Rapid and sustained antidepressant effects of vaporized N,N-Dimethyltryptamine: A Phase 2a clinical trial in Treatment-Resistant Depression. · April 18, 2025 · 10 min
Explore listener stats, chart rankings, contacts and more on the NPP BrainPod podcast page.